Business
Insulet develops and sells the Omnipod tubeless insulin-delivery system.
Insulet converted rapid Omnipod adoption into 31% growth, higher profit and strong free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 30.7%OK
- Profitability — Net income declined 40.9% to $247.1M from $418.3MWatch
- Cash flow — Free cash flow grew 23.7% to $377.7M from $305.3MOK
- Margins — Operating margin expanded 259 bps to 17.50%OK
- Accounting — Exceptional insulin-delivery growthNote
- Insiders — 5 purchases and 6 salesOK
Where the revenue comes from
Fiscal 2025, as INSULET CORP reports it. History and quarterly detail are in the app.
- Total Omnipod products$2.7B
- U.S.$1.9B
- International$754.3M
- Drug Delivery$34.1M
Leadership changes
From INSULET CORP's own filings, the day they're filed.
- Robbie Huffines · director · appointmenteff. 2025-10-31
- P. Morgan Chase · departureeff. 2025-10-31
- Ana M. Chadwick · President · appointmenteff. 2025-09-16
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-05-26
- 8-K · Company announcement2026-05-21
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about INSULET CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.